[go: up one dir, main page]

WO1999047172A3 - Oral pharmaceutical compositions to be taken without liquids, which contain inclusion complexes - Google Patents

Oral pharmaceutical compositions to be taken without liquids, which contain inclusion complexes Download PDF

Info

Publication number
WO1999047172A3
WO1999047172A3 PCT/EP1999/001540 EP9901540W WO9947172A3 WO 1999047172 A3 WO1999047172 A3 WO 1999047172A3 EP 9901540 W EP9901540 W EP 9901540W WO 9947172 A3 WO9947172 A3 WO 9947172A3
Authority
WO
WIPO (PCT)
Prior art keywords
liquids
pharmaceutical compositions
inclusion complexes
taken
oral pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP1999/001540
Other languages
French (fr)
Other versions
WO1999047172A2 (en
Inventor
Giancarlo Santus
Roberto Golzi
Caterina Lazzarini
Luciano Marcelloni
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Recordati SA
Original Assignee
Recordati SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Recordati SA filed Critical Recordati SA
Priority to AU29326/99A priority Critical patent/AU2932699A/en
Publication of WO1999047172A2 publication Critical patent/WO1999047172A2/en
Publication of WO1999047172A3 publication Critical patent/WO1999047172A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A61K9/0058—Chewing gums

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Disclosed are pharmaceutical compositions for oral administration which contain inclusion complexes and are characterised by rapid release of the active ingredient and the fact that they require no use of liquids for administration, being the saliva present in the oral cavity adequate for dissolution of the active ingredient. Said formulations are particularly useful in increasing the bioavailability of active ingredients which are insoluble or slightly soluble in water.
PCT/EP1999/001540 1998-03-13 1999-03-10 Oral pharmaceutical compositions to be taken without liquids, which contain inclusion complexes Ceased WO1999047172A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU29326/99A AU2932699A (en) 1998-03-13 1999-03-10 Oral pharmaceutical compositions to be taken without liquids, which contain inclusion complexes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITMI98A000511 1998-03-13
IT98MI000511A IT1298732B1 (en) 1998-03-13 1998-03-13 ORAL PHARMACEUTICAL COMPOSITIONS ASSUMABLE WITHOUT LIQUIDS, CONTAINING INCLUSION COMPLEXES

Publications (2)

Publication Number Publication Date
WO1999047172A2 WO1999047172A2 (en) 1999-09-23
WO1999047172A3 true WO1999047172A3 (en) 1999-11-11

Family

ID=11379303

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1999/001540 Ceased WO1999047172A2 (en) 1998-03-13 1999-03-10 Oral pharmaceutical compositions to be taken without liquids, which contain inclusion complexes

Country Status (3)

Country Link
AU (1) AU2932699A (en)
IT (1) IT1298732B1 (en)
WO (1) WO1999047172A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN190018B (en) * 1999-09-28 2003-05-31 Panacea Biotec Ltd
DK1309315T3 (en) * 2000-08-18 2006-10-09 Pharmacia Corp Rapidly disintegrating oral valdecoxib formulation
TWI321054B (en) * 2000-12-19 2010-03-01 California Inst Of Techn Compositions containing inclusion complexes
EP1258241A1 (en) * 2001-05-16 2002-11-20 BIOPROGRESS S.p.A. Method of increasing the bioavailability of nimesulide
PT1534340E (en) 2002-09-06 2012-03-13 Cerulean Pharma Inc Cyclodextrin-based polymers for delivering the therapeutic agents covalently bound thereto
AU2003295344B2 (en) 2002-10-09 2008-01-31 Insert Therapeutics, Inc. Cyclodextrin-based materials, compositions and uses related thereto
AR053023A1 (en) * 2005-02-25 2007-04-18 Recordati Ireland Ltd LERCANIDIPINE FREE BASE, METHODS FOR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
US20080176958A1 (en) 2007-01-24 2008-07-24 Insert Therapeutics, Inc. Cyclodextrin-based polymers for therapeutics delivery
US20140094432A1 (en) 2012-10-02 2014-04-03 Cerulean Pharma Inc. Methods and systems for polymer precipitation and generation of particles

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0449731A1 (en) * 1990-03-28 1991-10-02 Laboratoires Crinex Anti-inflammatory and/or analgesic pharmaceutical composition for perlingual administration
WO1991017774A1 (en) * 1990-05-22 1991-11-28 Boehringer Ingelheim Italia S.P.A. Inclusion compounds of nimesulide with cyclodextrins
EP0490193A1 (en) * 1990-11-30 1992-06-17 MEDICE Chem.-Pharm. Fabrik Pütter GmbH & Co. KG Complex of an actif enantiomer of ibuprofen with cyclodextrin
WO1994002177A1 (en) * 1992-07-28 1994-02-03 Boehringer Ingelheim Italia S.P.A. Method of preparation of inclusion compounds of nimesulide with cyclodextrins
WO1995015155A1 (en) * 1993-12-03 1995-06-08 Smithkline Beecham Farmaceutici S.P.A. Taste masked composition containing a drug/polymer complex
WO1997041843A2 (en) * 1996-05-03 1997-11-13 Atp Avant-Garde Technologies & Product Medicated chewing gum with a pleasant taste containing an inclusion complex
CN1176784A (en) * 1997-07-24 1998-03-25 北京路德有限责任公司 Method for preparing masticatory tablet of acetaminophen, and the product thereof

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0449731A1 (en) * 1990-03-28 1991-10-02 Laboratoires Crinex Anti-inflammatory and/or analgesic pharmaceutical composition for perlingual administration
WO1991017774A1 (en) * 1990-05-22 1991-11-28 Boehringer Ingelheim Italia S.P.A. Inclusion compounds of nimesulide with cyclodextrins
EP0490193A1 (en) * 1990-11-30 1992-06-17 MEDICE Chem.-Pharm. Fabrik Pütter GmbH & Co. KG Complex of an actif enantiomer of ibuprofen with cyclodextrin
WO1994002177A1 (en) * 1992-07-28 1994-02-03 Boehringer Ingelheim Italia S.P.A. Method of preparation of inclusion compounds of nimesulide with cyclodextrins
WO1995015155A1 (en) * 1993-12-03 1995-06-08 Smithkline Beecham Farmaceutici S.P.A. Taste masked composition containing a drug/polymer complex
WO1997041843A2 (en) * 1996-05-03 1997-11-13 Atp Avant-Garde Technologies & Product Medicated chewing gum with a pleasant taste containing an inclusion complex
CN1176784A (en) * 1997-07-24 1998-03-25 北京路德有限责任公司 Method for preparing masticatory tablet of acetaminophen, and the product thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE EPODOC EUROPEAN PATENT OFFICE; 25 March 1998 (1998-03-25), XP002111791 *

Also Published As

Publication number Publication date
ITMI980511A1 (en) 1999-09-13
IT1298732B1 (en) 2000-02-02
WO1999047172A2 (en) 1999-09-23
AU2932699A (en) 1999-10-11

Similar Documents

Publication Publication Date Title
LT2000064A (en) Flash-melt oral dosage formulation
WO2002080976A3 (en) Hsa-free formulations of interferon-beta
HUP0200248A3 (en) Oxamic acids and derivatives as thyroid receptor ligands, pharmaceutical compositions containing them as active ingredient and their use
BG66093B1 (en) Controlled release compositions comprising nimesulide
CA2337046A1 (en) Sustained release pharmaceutical preparation
WO2002074238A3 (en) Water soluble and palatable complexes
BR9913857A (en) Protein formulations
HUP0203451A2 (en) Pharmaceutical compositions of anti-tubercular drugs and process for their preparation
CA2371940A1 (en) Pregelatinized starch in a controlled release formulation
IL145789A0 (en) Derivatives of propionic acid, their preparation and pharmaceutical compositions containing them
AU2003229555A1 (en) Oral administration form for difficulty soluble basic active ingredients which are applied orally
BRPI0015567B8 (en) compound, pharmaceutical composition, dosage unit form, use of the pharmaceutical composition and method for preparing a pharmaceutical composition
NO20000284D0 (en) Tannic acid polymer compositions for controlled release of pharmaceutical agents, especially in the oral cavity
WO2002019969A3 (en) (5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents
CA2251886A1 (en) An oral pharmaceutical formulation containing ibandronate
EP0966966A3 (en) Nefazodone dosage form
BG105173A (en) Novel salt form of pantoprazole
HUP0400832A3 (en) New amidoalkyl-piperidine and amidoalkyl-piperazine derivatives, and pharmaceutical compositions containing such derivatives as active ingredients
DE69923336D1 (en) ORANGE BUPRENORPHINIC MEDICINAL PRODUCTS TO BE APPLIED
WO2002024203A3 (en) Controlled release formulations for oral administration
CA2338794A1 (en) New oral formulation for 5-ht4 agonists or antagonists
HUP0302193A3 (en) 1,4-diazabicyclo[3.2.2]nonabenzoxazole, -benzothiazole and benzimidazole derivatives, preparation thereof and pharmaceutical compositions containing them
WO1999047172A3 (en) Oral pharmaceutical compositions to be taken without liquids, which contain inclusion complexes
WO2003061557A3 (en) Levothyroxine pharmaceutical compositions, methods of making and methods of administration
WO2003013441A3 (en) Levothyroxine compositions and methods

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
NENP Non-entry into the national phase

Ref country code: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA